{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-24-007096","form_type":"8-K","ticker":"DWTX","cik":"0001818844","company_name":"Dogwood Therapeutics, Inc.","filed_at":"2024-05-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:20.338454+00:00","generated_at":"2026-06-02T19:41:32.549322+00:00","sec_items":["3.01"],"event_type":"regulatory","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Virios receives Nasdaq deficiency notice for bid price; requests hearing to seek compliance extension","bullets":["Second Nasdaq letter received May 1, 2024 for failure to maintain $1.00 minimum bid price.","Initial 180-day compliance period expired April 30, 2024; company has requested a hearing to stay delisting.","Plan to regain compliance includes IMC-2 Long-COVID study data from Bateman Horne Center and potential reverse stock split.","Hearing before Nasdaq panel will determine extension; common stock (VIRI) remains listed pending decision."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-24-007096","json":"https://secwatch.observer/filing/0001558370-24-007096.json","markdown":"https://secwatch.observer/filing/0001558370-24-007096.md","text":"https://secwatch.observer/filing/0001558370-24-007096.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1818844/000155837024007096/0001558370-24-007096-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1818844/000155837024007096/tmb-20240501x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T19:41:32.549322+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"0656aebc9441b287f2c72b7f31804dafa180a9e2","claim":"Dogwood Therapeutics, Inc. received a nasdaq deficiency notice notice regarding minimum bid price.","evidence_excerpt":"May 1, 2024, we received another letter from Nasdaq informing us that our shares had failed to comply with the $1.00 minimum bid price required for continued listing. In accordance with the latest letter and established Nasdaq procedures, we have requested a hearing with Nasdaq, at which, we will seek to extend the period during which we will seek to regain compliance. Our request for such hearing has stayed the delisting of our common stock pending a Nasdaq hearings panel’s (the “Panel”) decision. We intend to present a plan to regain compliance to the Panel that includes a discussion of the","evidence_source":"SEC 8-K Item 3.01","evidence_url":"https://www.sec.gov/Archives/edgar/data/1818844/000155837024007096/0001558370-24-007096-index.htm","confidence":0.95,"family_label":"Listing & Compliance Notices","details":[{"label":"Exchange","value":"nasdaq"},{"label":"Notice","value":"deficiency notice"},{"label":"Deficiency","value":"minimum bid price"}],"fact_type":"exchange_compliance_notice"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}